The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. The main questions it aims to answer are:

Does one year of treatment with ticagrelor plus aspirin (dual antiplatelet therapy) after CABG reduce the risk of major adverse cardiovascular events (MACE) over 10 years compared with aspirin alone or ticagrelor alone?

What are the long-term safety outcomes, including major bleeding events, among patients who received different antiplatelet strategies?

Researchers will compare the three originally randomized groups (ticagrelor plus aspirin, ticagrelor alone, and aspirin alone) to see if a one-year course of dual antiplatelet therapy provides a sustained clinical benefit over a decade.

Participants will:

Be contacted by telephone by the central study team for a one-time follow-up interview.

Provide information about their current health status, any cardiovascular events (such as heart attack, stroke, or repeat revascularization procedures) that have occurred since the last follow-up.

Report their current use of medications, including antiplatelet and other cardiovascular drugs.

Allow researchers to request relevant medical records to verify any reported clinical events.

Inclusion Criteria:

Original enrollment and randomization in the DACAB trial

Exclusion Criteria:

Who explicitly refuse to provide informed consent for the 10-year follow-up

All 500 patients who were enrolled and randomized in the DACAB trial (NCT02201771) between July 2014 and November 2015. These patients underwent elective isolated coronary artery bypass grafting (CABG) with saphenous vein grafting at six tertiary hospitals in China.

For this 10-year extended follow-up study, all original DACAB participants are eligible, regardless of their vital status or medication use during the follow-up period. Information on deceased participants will be collected from medical records, family members, or the national China Centre for Disease Control database to minimize loss to follow-up bias.